FDA Flags Heart Inflammation Risk Over Novavax COVID-19 Vaccine

FDA staff on Friday flagged the risk of heart inflammation following the administration of the Novavax COVID-19 vaccine.  In the company’s nearly 30,000 patient trial, conducted between December 2020 and September 2021, there were four cases of myocarditis detected within 20 days post-vaccination, the Epoch Times reports.

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Powered by WordPress | Designed by: Premium WordPress Themes | Thanks to Themes Gallery, Bromoney and Wordpress Themes